نتائج البحث

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

• Authors : Zinman B; Inzucchi SE ...

Subjects: Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/*therapeutic use ; Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*epidemiology

• Source: Diabetologia [Diabetologia] 2018 Jul; Vol. 61 (7), pp. 1522-1527. Date of Electronic Publication: 2018 Apr 30.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

• Authors : Sattar N; British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. .; Fitchett D

Subjects: Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/*therapeutic use ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucosides/Glucosides/Glucosides/*therapeutic use

• Source: Diabetologia [Diabetologia] 2018 Oct; Vol. 61 (10), pp. 2155-2163. Date of Electronic Publication: 2018 Jul 31.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.

• Authors : Natali A; Department of Clinical and Experimental Medicine, Pisa University, Via Savi 27, 56100, Pisa, Italy.; Nesti L

Subjects: Disease Progression*; Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/*therapeutic use ; Cardiomyopathies/Cardiomyopathies/Cardiomyopathies/*drug therapy

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2017 Oct 12; Vol. 16 (1), pp. 130. Date of Electronic Publication: 2017 Oct 12.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

The EMPA-REG outcome study: critical appraisal and potential clinical implications.

• Authors : Perseghin G; Metabolic Medicine, Policlinico di Monza & Department of Biomedical Sciences for Health, University of Milan, Via Amati 111, 20900, Monza, Italy. .; Solini A

Subjects: Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/*therapeutic use ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*drug therapy ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2016 Jun 04; Vol. 15, pp. 85. Date of Electronic Publication: 2016 Jun 04.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).

• Authors : Zinman B; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. .; Inzucchi SE

Subjects: Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/*therapeutic use ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*drug therapy ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2014 Jun 19; Vol. 13, pp. 102. Date of Electronic Publication: 2014 Jun 19.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

• Authors : Yu, J; Zhou, Z; Mahaffey, KW

Subjects: Clinical Trials and Supportive Activities; Cardiovascular; Heart Disease

• Source: urn:ISSN:0167-5273 ; urn:ISSN:1874-1754 ; International Journal of Cardiology, 324, 165-172

تفاصيل العنوان

Histological Study of the Effects of Empagliflozin Therapy on the Myocardium of Hypertensive Wister Adult Male Albino Rats.

• Authors : Farag Al-Mwafy, Marwa Ebrahim¹ ; Eskander, Fotna Gobran¹; Ali Attia, Mona Mohammed¹

• Source: Egyptian Journal of Histology. Sep2024, Vol. 47 Issue 3, p1157-1170. 14p.

تفاصيل العنوان

Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.

• Authors : Pellicori, Pierpaolo¹ (AUTHOR) ; Fitchett, David² (AUTHOR); Kosiborod, Mikhail N.^3,4 (AUTHOR)

• Source: European Journal of Heart Failure. Jul2021, Vol. 23 Issue 7, p1085-1093. 9p. 3 Charts, 2 Graphs.

تفاصيل العنوان

Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity.

• Authors : Kalra, Sanjay¹ ; Sahay, Rakesh²

• Source: Indian Journal of Endocrinology & Metabolism. Jan/Feb2017, Vol. 21 Issue 1, p245-248. 4p.

تفاصيل العنوان

Treatment outcomes of graded dose of empagliflozin in type-2 diabetes: A real world study.

• Authors : Dutta D; Department of Endocrinology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism Super Speciality Clinics, New Delhi, India.; Sharma M

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/therapeutic use; Benzhydryl Compounds

• Source: Annals of African medicine [Ann Afr Med] 2022 Jan-Mar; Vol. 21 (1), pp. 26-33.Publisher: Medknow Publications Country of Publication: India NLM ID: 101231417 Publication Model: Print Cited Medium: Internet ISSN: 0975-5764

تفاصيل العنوان